Actelion: EMA concludes safety review of Uptravi, decides that the medicine can continue to be used according to the prescribing information
The European Medicines Agency (EMA) has completed the review of Uptravi (selexipag) which was initiated following 5 patient deaths in France. EMA confirms that the medicine can continue to be used by both new and existing patients, according to the current prescribing information. No changes to the prescribing information are considered necessary following the review.